申请人:Asahi Kasei Pharma Corporation
公开号:EP3733665A1
公开(公告)日:2020-11-04
A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
一种由下式通式(1)代表的新型化合物或其盐,具有优异的 EP4 受体激动剂活性,以及一种以该化合物或其盐为活性成分的药物,可用于促进骨生成、治疗和/或促进骨折愈合等。